Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab; Other · Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Tipifarnib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 65 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22)
Interventions: Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Methotrexate, Prednisone, Vincristine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Maternal Cardiometabolic Health, Molecular Impact of Psychological Stress and Socioeconomic Adversity, Maternal Inflammatory Markers, Maternal Diabetes, Maternal Behavior, Maternal Distress
Interventions: Mindfulness Intervention; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Neuroendocrine Carcinoma
Interventions: 68Ga-DOTATATE, Positron Emission Tomography (PET) Scan; Drug · Diagnostic Test
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Streptococcal Pharyngitis
Interventions: Identifying group A strep carriers; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 5 Years to 15 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Pain, Opioid Use Disorder
Interventions: Emotional Awareness and Expression Therapy (EAET); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infection
Interventions: PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autism
Interventions: Not listed
Lead sponsor: SynapDx; Industry
Eligibility: 18 Months to 60 Months
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Scottsdale, Arizona • Long Beach, California • Sacramento, California + 15 more

Conditions: Allergic Asthma
Interventions: Omalizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Dilated Cardiomyopathy
Interventions: Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 2
States / cities: Denver, Colorado • Salt Lake City, Utah

Conditions: Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years and older
Enrollment: 2,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endothelial Dysfunction, Inflammation in Cardiopulmonary and Vascular Disease States, Healthy Volunteers
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Inflammation, Nutrition Therapy
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 25 Years to 45 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: [18F]FluorThanatrace; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions: Salmeterol or Salmeterol/Fluticasone; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 40 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: REGN5678, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 24
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: NSCLC Stage IV, ALK Fusion Protein Expression
Interventions: Peptide vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sepsis
Interventions: Sepsis; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: A Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of Pennsylvania
Interventions: Art therapy; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Panitumumab, Surgery, Radiation Therapy; Drug · Procedure
Lead sponsor: Neal Ready; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Non-Hodgkin's Disease
Interventions: Nivolumab, Brentuximab Vedotin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 15 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Birmingham, Alabama • Miami, Florida • Tampa, Florida + 12 more

Conditions: Follicular Lymphoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meibomian Gland Dysfunction
Interventions: Meibomian gland (MG) expression; Procedure
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Conscious Pregnancy: Supporting Maternal Cardiometabolic Health With Mindfulness

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

GRoup A StrePtococcus

Emotional Awareness and Expression Therapy for Chronic Pain and Opioid Use Disorder

PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

SynapDx Autism Gene Expression Analysis Study (STORY)

Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research

Gene Expression and Inflammation in Overweight Subjects

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Evaluating Genes in Sputum to Measure Drug Response in COPD

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Expression Profiles of Integrin αDβ2 on Neutrophils in Sepsis

A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Clonal Evolution in Follicular Lymphoma

The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression